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Abstract
Background Previous studies suggest that physical exercise could slow dementia progression. However, evidence for the 
cost effectiveness of structured exercise is conflicting and based on small trials.
Objectives The objective of this study was to compare the cost effectiveness of a tailored, structured, moderate- to high-
intensity exercise programme versus usual care in people with mild to moderate dementia.
Methods An economic evaluation was conducted from the UK National Health Service and personal social services 
perspective, based on data from a large randomised controlled trial. The primary clinical outcome was the participant 
reported ADAS-Cog (Alzheimer’s Disease Assessment Scale–Cognitive Subscale) at 12 months. Costs (£; 2014–2015 
prices) were collected prospectively over a 12-month follow-up period. A bivariate regression of costs and quality-
adjusted life-years (QALYs), with multiple imputation of missing data, was conducted with the view to estimating 
the incremental cost per QALY gained and the incremental net monetary benefit (INMB) associated with the exercise 
programme plus usual care versus usual care. Sensitivity analyses were undertaken to assess the impact of uncertainty 
surrounding aspects of the economic evaluation, and pre-specified subgroup analyses explored heterogeneity in the 
cost-effectiveness results.
Results Participants (n = 494) were randomised to exercise plus usual care or usual care only. By 12 months the mean 
ADAS-Cog score had worsened slightly to 25.2 (standard deviation [SD] 12.3) in the exercise arm and 23.8 (SD 10.4) in the 
usual care: difference − 1.4, 95% confidence interval (CI) − 2.6 to − 0.2 (p = 0.03). The mean (standard error [SE]) costs 
over 12 months for experimental versus control was £5945 (US$7856) versus £4597 (US$6574), respectively; (difference: 
£1347 [$1926]; p = 0.0426). Mean (SE) QALY estimates were 0.787 (0.012) versus 0.826 (0.019), respectively (p = 0.090). 
The probability that the exercise programme is cost effective was < 1% across cost-effectiveness thresholds. INMBs ranged 
between –£2601 (US$3719) and £2158 (US$3086) at cost-effectiveness thresholds between £15,000 (US$21,450) and 
£30,000 (US$42,900) per QALY. The cost-effectiveness results remained robust to several sensitivity and subgroup analyses.
Conclusions Building on the clinical results of the trial, which showed that the structured exercise programme evaluated 
does not slow cognitive impairment in people with mild to moderate dementia, this economic evaluation shows that the 
programme is not cost effective.
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section.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4166 9-018-0097-9) contains 
supplementary material, which is available to authorized users.
 * Iftekhar Khan 
 i.khan.2@warwick.ac.uk
Extended author information available on the last page of the article
 I. Khan et al.
Key Points for Decision Makers 
This study is the largest randomised controlled trial to 
date that evaluates the cost effectiveness of structured 
exercise in in people with dementia.
Structured exercise is shown not to be cost effective for 
people with dementia.
Patients became physically fitter due to exercise; these 
benefits did not translate into improvements in important 
cognitive outcomes.
1 Introduction
Dementia is a syndrome characterised by acquired, progres-
sive deterioration in memory, general cognitive function, 
self-care and personality. It affects mainly older people. 
Dementia prevalence in developed countries approximately 
doubles in successive 5-year age groups between 65 and 
99 years, from under 1% for 65- to 69-year-olds to about 
35% in 95- to 99-year-olds [1]. Approximately 60% and 20% 
of dementia cases in developed countries are caused by Alz-
heimer’s disease and vascular dementia, respectively [2], 
whilst mixed Alzheimer’s/vascular dementia and dementia 
with Lewy bodies are other common causes. In the UK, 
there are approximately 670,000 dementia sufferers [3].
Although dementia prevalence has fallen in Western 
Europe and the USA [4, 5], the worldwide economic burden 
of dementia remains high at US$815 billion [6]. In the USA, 
this economic burden is estimated to be at least US$157 bil-
lion [7]. In Europe, it is approximately €250 billion (US$268 
billion) [8, 9], £23 billion [10] (US$35 billion) of which falls 
on the UK health services. The global cost is expected to rise 
to US$2 trillion by 2030 [6]; hence, reducing it is impor-
tant to healthcare systems worldwide. Moreover, common 
drug treatments offer modest efficacy with average annual 
acquisition costs, ranging from £948 (US$1197) to £996 
(US$1423) (56 tablet pack, depending on dose) for rivasti-
gamine and galantamine, respectively [11, 12], excluding 
costs associated with toxicity-related over-exposure (high 
dosing) or drug interactions [13]. The probability of cost 
effectiveness of these drug treatments does not exceed 20% 
at cost-effectiveness thresholds as high as £40,000 per addi-
tional quality-adjusted life-year (QALY) [14].
Current (drug) interventions aim to reduce risk and/or 
alleviate symptoms of, rather than cure, dementia. Some 
(mechanistic) studies have shown positive associations 
between physical activity and cognition [15] in humans. 
Structured exercise has been shown to offer benefit to 
dementia sufferers in several previous epidemiological 
studies [16–18]. In clinical studies, however, no confirma-
tory evidence on the effectiveness of exercise on dementia 
symptoms has been reported. This may be due to several fac-
tors associated with study design, heterogeneity in the popu-
lations, small sample sizes and exercise intensity. Moreover, 
evidence for the cost effectiveness of exercise in people with 
dementia is limited and based on small trials [19, 20].
We therefore present the results from a cost-effectiveness 
analysis of a high-intensity structured exercise intervention 
delivered in the context of the largest confirmatory ran-
domised controlled trial (RCT) reported to date.
2  Methods
2.1  Trial Background
The DAPA (Dementia and Physical Activity) RCT was a 
multicentre, pragmatic RCT. Individuals with a clinically 
confirmed diagnosis of dementia in accordance with the 
Diagnostic and Statistical Manual, 4th Edition (DSM-
IV), and a standardised Mini-Mental State Examination 
(sMMSE) score of > 10, were recruited from 15 regions 
across England between February 2013 and June 2015. Par-
ticipants were randomised (2:1 ratio) to either a moderate- 
to high-intensity, tailored structured exercise programme or 
usual practice.
The primary clinical outcome was the participant-
reported ADAS-Cog (Alzheimer’s Disease Assessment 
Scale–Cognitive Subscale) at 12 months. A total of 375 par-
ticipants were required to detect a difference of 2.45 ADAS-
Cog points (standardised effect of 0.31) in the ADAS-Cog 
(80% power, 5% type I error). Further details of the trial are 
reported elsewhere [21, 22].
2.2  Interventions
2.2.1  Exercise (Experimental)
The exercise intervention was divided into two parts: a 
supervised component (4 months) and an unsupervised 
component lasting an additional 8 months. The supervised 
component comprised a pre-exercise assessment and twice-
weekly exercise supervision by trained physiotherapists and 
exercise assistants of 60–90 min duration for 4 months with 
a target of at least 50 min of unsupervised activity at mod-
erate intensity, to achieve a total of 150 min per week. The 
exercises classes involved a combined aerobic and resistance 
training schedule at moderate to hard intensity, delivered in 
groups of up to eight participants.
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2.2.2  Usual Care (Control)
All participants received usual care consistent with the 
National Institute for Health and Care Excellence (NICE) 
clinical guidance [23]. This comprised counselling for car-
ers and families, clinical assessment, prescription of symp-
tomatic treatments and brief advice about physical activity 
[24, 25]. Treatment was determined by the participants’ 
physicians on the basis of clinical need and was monitored 
through the study period.
2.3  Overview of Economic Evaluation
The economic evaluation was designed as a cost-utility anal-
ysis with the cost effectiveness of the exercise intervention, 
compared with usual care, expressed in terms of incremental 
cost per QALY gained. The primary analysis was undertaken 
from the perspective of the UK National Health Service 
(NHS) and Personal Social Services (PSS), as recommended 
by NICE methodological guidance for technology appraisals 
and additionally from a societal perspective for the purposes 
of a sensitivity analysis [26]. A 12-month time horizon for 
the economic evaluation was used (12-month follow-up of 
RCT), and therefore no discounting was required.
2.4  Cost of the Exercise Programme
The costs relating to delivering the exercise programme, 
inclusive of training, delivery of group sessions, equipment 
(e.g. belts, weights, exercise bike), monitoring activities, 
follow-up, administrative activities, telephone contacts, 
supervision activities, travel costs and venue hire costs were 
estimated using weekly activity logs completed by physi-
otherapists and exercise assistants. Cost data were combined 
with attendance data to derive estimates of mean cost per 
session per attending participant for each group within each 
site.
2.5  Measurement of Broader Resource Use
Broader health and personal social service and broader 
societal resource inputs (for the purposes of a sensitivity 
analysis) were collected (through interviews) at baseline and 
6 and 12 months post-randomisation using a modified ver-
sion of the Client Services Receipt Inventory (CSRI; version 
1.0) [27, 28]. Resource use data included use of sheltered 
housing/care home accommodation, hospital and day-care 
services, community-based health and social care, and aids 
and equipment. Details of travel costs (borne by trial partici-
pants or family members or friends) due to the trial partici-
pants’ health status or contacts with health or social services 
were collected. Medication costs were derived from dose 
frequency and duration.
2.6  Valuation of Resource Use
Resource inputs were valued using primary research (e.g. 
participant travel costs, participant time taken off work) and 
data collated from secondary sources, with the valuation 
of the latter informed by national methodological guidance 
(Electronic Supplementary Material Appendix Table 1) [26].
Staff inputs associated with the delivery of the exercise 
programme were determined from hourly unit costs for each 
Agenda for Change band [29]; these included staff salaries, 
qualification costs, employer on-costs and associated rev-
enue and capital overheads. Travel costs (for each mile) were 
determined from the Automobile Association (AA) [30] and 
the Department for Transport Public Service Vehicle Survey 
[31]. Hospital inpatient admissions were valued using NHS 
Reference Costs trusts schedules [32]. Other hospital-based 
costs were valued using national tariffs [29, 32]. Community 
health and social care resource use was valued using second-
ary sources [29]. Participant-level costs for medication use 
were valued using Health and Social Care Information Cen-
tre (HSCIC) drug costs (2015) [11]. Gender-specific median 
earnings data were derived from self-reported work status 
information and used to estimate the costs of time taken 
off work (by family members/carers or participants). Other 
family-borne costs were also determined. The NHS Hospital 
and Community Health Services Pay and Prices Index was 
used to inflate/deflate costs where necessary to 2014–2015 
prices (£ sterling) [33].
2.7  Health‑Related Quality of Life: Health Utilities 
and QALYs
Health-related quality of life (HRQoL) of participants was 
assessed by both participants and carers using the EuroQol 
EQ-5D-3L [34] at baseline and 6 and 12 months post-ran-
domisation for generating QALY profiles. The EQ-5D-3L 
consists of a descriptive system, which defines HRQoL 
across five dimensions: ‘mobility’, ‘self-care’, ‘usual activi-
ties’, ‘pain/discomfort’ and ‘anxiety/depression’. Responses 
in each dimension are scored as no problems (1), some or 
moderate problems (2) and severe or extreme problems 
(3). The UK time trade-off tariff was applied to each set of 
responses to generate an EQ-5D-3L utility score for each 
trial participant [34]. Resulting utility scores range from 
− 0.59 to 1.0, with 0 representing death and 1.0 represent-
ing full health; values below 0 are indicative of health states 
worse than death. The visual analogue scale (VAS) of the 
EQ-5D-3L, ranging from 100 (best imaginable health state) 
to 0 (worst imaginable health state), was included in the 
assessments. QALYs were calculated as the area under the 
baseline-adjusted utility curve using linear interpolation 
between baseline and 6 and 12 months, with the adjustment 
 I. Khan et al.
process accounting for variation in baseline utility values 
[35].
2.8  Missing Data
Multiple imputation (MI) using the method of chained 
equations (MCMC) was used for the base-case analysis to 
impute missing resource use and HRQoL data [36], taking 
into account covariates including baseline costs, baseline 
utilities, age, gender and baseline MMSE score (< 20; ≥ 20). 
Mean matching using predictive methods was used to 
improve estimates of imputed values since normality could 
not be assumed. Each imputed dataset was analysed indepen-
dently using model-based approaches; estimates were pooled 
to generate mean and variance estimates of costs and QALYs 
using Rubin’s rule to capture within and between variances 
for imputed samples [37]. Information loss from finite impu-
tation sampling was minimised using 20 datasets, resulting 
in minimal loss of efficiency (< 0.5%) [38]. Since the frac-
tion of information missing was reasonably low, 20 imputa-
tion sets were considered adequate. Imputed and observed 
values were compared to establish that imputation did not 
introduce bias into subsequent estimation [38].
2.9  Cost‑Effectiveness Analyses
Mean resource use, cost and utility values were compared 
between groups using two sample t-tests. Differences 
between groups, along with confidence intervals (CIs) were 
estimated using non-parametric bootstrap estimates (10,000 
replications) [26]. Seemingly unrelated regression (SUR) 
methods that account for the correlation between costs and 
outcomes were used to estimate mean incremental costs 
and QALYs whilst adjusting for covariates (baseline costs, 
baseline utilities, age, gender, and baseline MMSE score 
(< 20; ≥ 20). Non-parametric bootstrap methods were used 
to generate the joint distributions of costs and outcomes to 
populate the cost-effectiveness plane. Bias-corrected non-
parametric bootstrapping was used so that the sample cor-
relation structure was preserved.
The incremental cost-effectiveness ratio (ICER) was esti-
mated as the difference between groups in mean total costs 
divided by the difference in mean total QALYs. Mean ICER 
values were compared against cost-effectiveness threshold 
values [39] ranging between £15,000 (US$21,450) and 
£30,000 (US$42,900) per QALY using 2015 purchasing 
power parities (£1 = US$1.43) [33], thereby encompassing 
threshold values recommended by NICE. The cost-effective-
ness thresholds provide an indication of society’s willing-
ness to pay for an additional QALY; lower ICER values than 
the threshold could be considered cost effective for use in 
the UK NHS. The incremental net monetary benefit (INMB) 
of switching from usual care to an exercise programme was 
also reported. The INMB describes the resource gain (or 
loss) when investing in a new intervention when resources 
can be used elsewhere at the same cost-effectiveness thresh-
old. Cost-effectiveness acceptability curves (CEACs) show-
ing the probability of the exercise programme being cost 
effective over the range of cost-effectiveness thresholds were 
generated. All analyses were conducted in  SAS® version 9.4 
(SAS Institute, Cary, NC, USA) on a Microsoft Windows 
(Microsoft Corp., Redmond, WA, USA) platform.
2.10  Sensitivity and Subgroup Analyses
Several pre-specified sensitivity analyses were undertaken 
to assess the impact on the base-case economic evalua-
tion. These included a complete cases analysis, adopting a 
wider societal perspective that included costs incurred by all 
sectors of the economy, recalculating QALYs using carer-
reported EQ-5D-3L values, recalculating the average cost 
per participant per exercise session by taking into account 
practitioner travel costs, varying the cohort size for the 
exercise programme between the lowest (n = 3) and highest 
(n = 10) number of participants attending across all exer-
cise groups, and setting the venue hire costs to zero (on the 
assumption that delivery of the exercise programme in rou-
tine UK NHS settings, rather than community venues, may 
be associated with zero opportunity costs). Pre-specified 
subgroup analyses were conducted by gender (male, female) 
and baseline MMSE score (< 20, ≥20).
3  Results
3.1  Study Population and Clinical Results
From the 494 participants randomised (329 to the exercise 
programme and 165 to usual care), complete baseline infor-
mation was available for 488 participants (326 for exercise 
and 162 for control) for the base-case economic evaluation. 
Between 91 and 99% and 91 and 98% of health resource use 
data were complete at baseline for the exercise and usual 
care groups, respectively (Table 1 and Electronic Supple-
mentary Material Appendix Table 2).
Complete QALY profiles were available for 435 (88%) 
participants based on the participant-reported EQ-5D-3L 
(84% for the carer-reported EQ-5D-3L). There was no clini-
cal benefit based on the primary ADAS-Cog outcome: the 
mean ADAS-Cog was 25.2 (standard deviation [SD] 12.3) 
compared with 23.8 (SD 10.4) for exercise versus usual care, 
with an adjusted mean difference of –1.4 (95% CI − 2.6 to 
− 0.2; p = 0.026) [22] (higher scores reflect worse outcomes 
for ADAS-Cog). Further details of the clinical results of the 
trial can be found elsewhere [22].
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3.2  Cost of Intervention
The intervention cost components are reported under four 
main headings: (i) staff costs, inclusive of training activities, 
planning, direct delivery, administrative activities, meetings 
with professionals, telephone calls and supervision activi-
ties associated with group delivery; (ii) travel costs, based 
on distances travelled by practitioners by mode of transport; 
(iii) venue hire costs; and (iv) equipment and other costs 
for each site, including cost of belts, stopwatches, timers, 
cones, lap counters, CDs, stationery (e.g. pens, erasers) and 
trial manuals, associated with group delivery. Total interven-
tion costs are also presented within each group within each 
site (Electronic Supplementary Material Appendix Table 3). 
These varied between £4444 (US$6355) (Worcester, cohort 
53) and £11,342 (US$16,219) (Wolverhampton, cohort 50). 
The average costs per exercise session per participant varied 
from about £29 (US$41) (Amersham, cohort 4), to £108 
(US$154) (Atrium, cohort 9).
3.3  Broader Resource Use
Broader resource use values are presented for participants 
with complete data by trial allocation, resource use cate-
gory and study period (Electronic Supplementary Material 
Appendix Table 4).
Amongst participants with complete resource use data, 
the most frequent health resource inputs were general prac-
titioner (GP) visits, hospital stays, practice nurse visits and 
community psychiatrist contacts. On average, there were no 
statistical differences in broader health resource use between 
groups (Electronic Supplementary Material Appendix 
Table 4). The mean (standard error [SE]) number of GP 
contacts per participant over 12 months was 1.8 (0.14) in 
the exercise arm compared with 1.7 (0.27) in the usual care 
arm (p = 0.876). Community mental healthcare services, pri-
marily through psychiatric support, were used by a smaller 
proportion of participants in the exercise group at 12 months 
(10% [28/280] vs. 14% [19/136]; p = 0.224). No noticeable 
differences in terms of other healthcare resource use were 
observed between baseline and 12 months for hospital stays, 
practice nurse visits and community psychiatrist contacts. 
Resource use frequencies in other categories were low; 
hence, meaningful comparisons could not be easily made 
(Electronic Supplementary Material Appendix Table 4).
3.4  Economic Costs
With the exception of the cost of the exercise intervention, 
there were no statistically significant differences between the 
trial groups in any cost category between randomisation and 
12 months (Table 2).
The mean cost of the exercise programme over the entire 
follow-up period was £1269 (US$1815). Mean total NHS 
and personal social service costs, inclusive of the cost of the 
intervention, were £5945 (US$8501) in the intervention arm 
compared with £4597 (US$6534) in the control arm, gen-
erating a mean cost difference of £1347 (US$1926) (boot-
strap 95% CI £8–2136 [US$11–3054]; p = 0.0426). Over the 
entire follow-up period, and for participants with complete 
data, mean total societal costs, inclusive of the cost of the 
intervention, were £6063 (US$8670) in the intervention arm 
compared with £4761 (US$6808) in the control arm, gener-
ating a mean cost difference of £1301 (US$1860) (bootstrap 
95% CI £3–2096 [US$4–2997]; p = 0.0479).
3.5  Health‑Related Quality of Life Outcomes
For complete cases, there were no statistically significant 
differences in participant- or carer-reported EQ-5D-3L util-
ity or EQ-5D VAS scores between the exercise and usual 
care groups. The mean (SE) participant reported QALY esti-
mate was 0.787 (0.012) versus 0.826 (0.019) (p = 0.090) for 
exercise versus usual care (Table 3); this was 0.758 (0.014) 
versus 0.782 (0.020) for the carer-reported EQ-5D-3L 
(p = 0.330).
3.6  Cost‑Effectiveness Results: Base‑Case Analysis
The baseline economic evaluation, using imputed attribut-
able costs and QALYs with covariate adjustment, resulted 
in mean total costs of £5580 (US$7974) in the exercise 
group compared with £3917 (US$5601) in the usual care 
Table 1  Summary of economic data completion and demographics
CSRI Client Services Receipt Inventory, QALY quality-adjusted life-
year, SD standard deviation
a A full QALY profile estimable between baseline and 12 months
Economic data/demographic characteristic Exercise
(n = 329)
Usual care
(n = 165)
Age (years) [mean (SD)] 76.9 (7.9) 78.4 (7.6)
Gender (male) [n (%)] 195 (59.3) 106 (64.2)
Ethnicity [n (%)]
 White 321 (97.6) 157 (95.2)
 Other 8 (2.4) 8 (4.8)
Health resource use (CSRI) completion (minimum–maximum [%])
 Baseline 91–98 91–99
 6 months 76–86 84–91
 12 Months 75–82 78–85
EQ-5D-3L utility (participant) completion (%)
 Baseline 98 96
 6 months 88 83
 12 Months 78 75
QALY (participants)  completiona 88 87
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group, a mean incremental cost of £1663 (US$2378). The 
mean incremental cost-effectiveness of the exercise inter-
vention was estimated to be − £74,227 (− US$106,145) 
per QALY, i.e. on average, the experimental interven-
tion was associated with a higher cost and a lower effect 
and was dominated in health economic terms. The asso-
ciated mean INMB at cost-effectiveness thresholds of 
£15,000, £20,000 and £30,000 per QALY were − £2158 
(−  US$3086), −  £2306 (−  US$3298) and −  £2601 
(− US$3719), respectively (Table 4). The base-case mean 
INMB was < 0, suggesting that the exercise group would 
result in an average net economic loss of about £2158 
(US$3086) (INMB = − £2,158, 95% CI − £3455 to − £969 
[− US$4941 to − US$1386]). The cost-effectiveness plane 
(Fig. 1) shows that the vast majority of the ICER values lie 
in the north-west quadrant.
The subsequent probability of cost effectiveness is close 
to zero (Fig. 1), i.e. if decision-makers are willing to pay 
between £15,000 and £30,000 for an additional QALY, the 
probability that the exercise intervention is cost effective 
is < 1% (Table 4).
3.7  Sensitivity Analyses
The probability that the exercise intervention is cost effec-
tive remained relatively static (< 1%) for the majority of 
the sensitivity analyses (complete cases, societal costs, 
carer-reported EQ-5D, inclusion of practitioner travel costs, 
changes in the number of participants per cohort to the lowest 
number observed). When venue hire costs were excluded and 
the number of participants per cohort was set at the highest 
number observed across all groups, the probability that the 
Table 2  Economic costs for complete cases by trial allocation, study period and cost category (£; 2014–2015 prices): randomisation to 
12 months (n = 416 total; n = 280 exercise and n = 136 usual care)
CI confidence interval, NHS National Health Service, PSS personal social services, SE standard error
*Statistically significant at the 2-sided 5% level
a p value calculated using student’s t-test, 2-tail unequal variance
b Non-parametric bootstrap estimation using 10,000 replications, bias corrected
c Participant travel consisted of ambulance or NHS-supported travel
d Participant travel consisted of private transport costs (e.g. private taxi)
Cost category by period Exercise [mean (SE)] Usual care [mean (SE)] Mean difference p-valuea Bootstrap 95%  CIb
NHS/PSS costs
 Patient accommodation 187.6 (58.02) 54.4 (30.16) 133.2 0.0513 − 6.9 to 210.8
 Hospital services 2019.3 (466.80) 1827 (320.04) 192.3 0.7342 − 1001.9 to 858.1
 Day-care services 33.9 (4.82) 49.2 (10.25) − 15.3 0.1685 − 36.9 to 1.12
 General community health services 366.3 (38.25) 347.6 (27.88) 18.7 0.6438 − 62.3 to 64.9
 Community mental health services 163.6 (27.08) 150.2 (23.81) 13.4 0.7108 − 62.2 to 56.3
 Social care services 647 (123.9) 759.9 (190.09) − 112.9 0.6190 − 565.3 to 169.3
 Equipment, adaptations/repairs 1.9 (0.62) 14.5 (10.23) − 12.6 0.2092 − 30.6 to 1.74
 Participant  travelc 5.7 (0.58) 7 (1.01) − 1.3 0.2651 − 3.6 to 0.16
 Concomitant/prescription medications 1046.2 (78.66) 1067.4 (161.72) − 21.2 0.9081 − 372.3 to 209.4
 Other 204.5 (37.86) 321 (184.50) − 116.5 0.5366 − 466.4 to 140.4
 Total (NHS/PSS) 4676.2 (507.66) 4597.3 (444.35) 78.7 0.9066 − 1336.7 to 880.3
Broader societal costs
 Privately provided general community health 
services
9.1 (4.32) 3.4 (2.33) 5.7 0.2431 − 4.8 to 11.4
 Privately provided mental health services 19.6 (5.35) 103.5 (73.61) − 83.9 0.2562 − 216.5 to 21.1
 Participant equipment 8.5 (4.12) 7.4 (4.77) 1.1 0.8617 − 11.8 to 8.8
 Participant  traveld 2.1 (0.57) 3.4 (0.97) − 1.3 0.2656 − 3.6 to 0.16
 Time off work (h) 13.8 (3.92) 10.3 (4.24) 3.5 0.5417 − 8.3 to 10.4
 Time off work (days) 65.2 (19.19) 35.8 (12.46) 29.4 0.2001 − 19.1 to 56.3
 Total broader societal costs 118.3 (20.55) 163.7 (20.01) − 45.4 0.0594 − 104.1 to 1.4
 Total (societal costs) 4794.3 (510.66) 4761.0 (447.24) 33.3 0.9609 − 1390.5 to 838.8
 Intervention costs 1268.7 (29.56)
 Total PSS/NHS including intervention costs 5944.9 (491.75) 4597.3 (444.35) 1347.4 0.0426 8.2 to 2135.7
 Total societal including intervention costs 6063.0 (494.08) 4761.1 (447.24) 1301.9 0.0479 2.8 to 2095.5
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exercise intervention is cost effective remained below 5%. 
The average INMB was unlikely to be positive as all upper 
95% confidence limits were below zero (Table 4 and Fig. 2).
3.8  Subgroup Analyses
The four pre-planned subgroup analyses showed no evidence 
that gender or the baseline MMSE score has a significant 
effect on the cost effectiveness of the exercise programme 
(Table 4 and Fig. 3).
4  Discussion
This trial-based economic evaluation revealed that a moder-
ate- to high-intensity aerobic and strength exercise programme 
delivered in community settings is not cost effective compared 
with usual care for adults with mild to moderate dementia. 
The INMB estimate was negative, a finding that remained 
robust to several sensitivity and subgroup analyses. The strong 
evidence against our structured exercise programme devel-
oped for people with mild to moderate dementia generated by 
this trial-based economic evaluation is unlikely to be altered 
by extrapolation of cost effectiveness over a longer time hori-
zon. Although it may be possible that there are cumulative or 
learning effects for which the benefits of the structured exer-
cise programme may manifest over the longer term, follow-up 
after 12 months did not appear to point to this [22].
The main reason for lack of cost effectiveness of the 
exercise intervention appears to stem from limited clinical 
benefit as well as it being more costly. We present a rigor-
ous evaluation of the costs involved (exceeding on average 
£100 per participant per session). This cost is higher than 
other experimental exercise interventions reported else-
where [19]. However, this is likely to be due to the inclu-
sion of more intensive support by trained physiotherapists 
and exercise assistants than other programmes as well as Ta
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Table 4  Participant- and carer-reported EQ-5D-3L quality-adjusted 
life-years (complete cases)
CI confidence interval, QALY quality-adjusted life-year, SE standard 
error
a Exercise versus usual care
QALY (EQ-5D-3L 
participant)
QALY (EQ-5D-3L 
carer)
n Mean (SE) n Mean (SE)
Exercise 294 0.787 (0.012) 279 0.758 (0.014)
Usual care 141 0.826 (0.019) 137 0.782 (0.020)
Mean  differencea − 0.039 − 0.024
p-value (95% CI) 0.090 (− 0.083 
to 0.0061)
0.330 
(− 0.073 to 
0.0324)
Cost Effectiveness of Structured Exercise in Dementia
several other cost components such as equipment and use 
of site in our calculation of the cost of the intervention. 
Although patients became physically fitter due to exer-
cise [21], these benefits did not translate into improve-
ments in mobility and functional activities that may have 
required demonstrating improved motor re-learning or 
cognitive outcomes. It is possible that carers are reluctant 
to encourage dementia sufferers to re-establish functional 
activities through fear of injury, although this remains to 
be elucidated through further research. Consequently, in 
the absence of any effect in either the primary clinical 
outcome or the EQ-5D-3L-based QALY, usual care was 
dominant in health economic terms. Unless exercise pro-
grammes are demonstrated to result in downstream cost 
Fig. 1  Cost-effectiveness plane. 
GBP British pounds, QALYs 
quality-adjusted life-years
Fig. 2  Cost-effectiveness 
acceptability curve. GBP Brit-
ish pounds
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savings and/or improvements in cognitive or HRQoL out-
comes, they are unlikely to be cost effective in resource-
constrained systems.
There is limited evidence for cost effectiveness of organ-
ised high-intensity exercise interventions in dementia 
patients reported in the broader literature. This cost-effec-
tiveness analysis using participant-level data is based on the 
largest RCT of its kind reported to date. The results from our 
analyses are consistent with a recent economic evaluation of 
exercise therapy for behavioural and psychological symp-
toms of dementia [19]. In that smaller RCT (n = 131 sub-
jects), exercise therapy was not cost effective. Our larger trial 
offers a confirmatory conclusion in this regard. In contrast, 
another smaller (n = 40) trial [20] suggests that community-
based exercise programmes confer cognitive and physical 
benefits with potential to show cost effectiveness, but this 
remains to be substantiated in larger well-controlled studies.
The main strengths of this analysis are that the trial was 
prospectively designed for a cost-effectiveness analysis using 
individual-level data to reach a confirmatory conclusion with 
respect to exercise training as an intervention in people with 
dementia. There were, however, several limitations to this 
cost-effectiveness analysis. Firstly, QALYs were based on util-
ity measurements at just two timepoints post-randomisation. 
Although the trial did not yield benefits, the assumption of lin-
earity of HRQoL between data collection points is uncertain 
and becomes more uncertain when missing data are present.
Secondly, despite the longitudinal nature of the study, 
resource use was retrospectively recalled by trial participants 
and carers, which is likely to have resulted in some recall 
bias; although the bias is likely to have been similar between 
randomised arms. Thirdly, a smaller pilot or phase II trial 
may have been useful in identifying the critical costs that 
drive cost effectiveness. Instead, data for a broad spectrum 
of cost categories were collected which, on average, had little 
impact on the ICER. Many costs items did not occur (Elec-
tronic Supplementary Material Appendix Tables 3 and 4) and 
a reduced form of the CSRI in this setting may be advisable 
with a focus on the largest and most relevant costs. In addi-
tion, the CSRI in several places could be improved as it leads 
to many categories of ‘other’ costs that are time consuming 
for data management. Many of these costs had little impact 
on the results. Sensitivity analyses, for example, showed the 
cohort size as the most influential factor on the INMB and not 
some of the cost components incorporated into the analysis.
Finally, the 95% CI for the incremental QALYs does not 
exclude the possibility of a small QALY benefit (the upper 
95% CI is greater than zero; Table 4). However, the upper 
limit of these intervals from the sensitivity analyses is less 
than about 0.03 (e.g. for the carer-reported EQ-5D-3L). 
Hence, for an observed base-case incremental cost of £1683 
(US$2407), the ICER is very unlikely to be cost effective 
even in the most optimistic scenario (i.e. £1683/0.03, an 
ICER of £56,100 [US$80,223] per QALY in the best case).
5  Conclusion
Data collected in the DAPA trial provides strong evidence 
that our structured, moderate- to high-intensity exercise 
Fig. 3  Sensitivity and subgroup analyses. CE cost effectiveness, CI confidence interval, INMB incremental net monetary benefit, LCL lower 95% 
confidence interval, MMSE Mini-Mental State Examination, QALY quality-adjusted life-year, UCL upper 95% confidence interval
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programme, in addition to usual care, is unlikely to be cost 
effective for mild to moderate dementia sufferers when com-
pared with usual care alone.
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